Control of Cardiac Output with Ivabradine or Beta-Blockers for Refractory Hypoxemia under Veno-Venous ECMO for Severe ARDS
Cardiovascular Drugs and Therapy · 2025
DOI: 10.1007/s10557-024-07650-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Drugs and Therapy, 2025. Verfasst von Paul Masi und 5 weiteren Autor:innen. Beteiligte Einrichtung: AP-HP, Hôpitaux Universitaires Henri-Mondor, Service de Médecine Intensive Réanimation, 94010, Créteil, France. paul.masi@aphp.fr. Hauptthemen laut MEDLINE: Ivabradine, Extracorporeal Membrane Oxygenation, Adrenergic beta-Antagonists, Respiratory Distress Syndrome. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Hypoxemia is a risk factor for mortality and long-term neuropsychological impairment during severe acute respiratory distress syndrome (ARDS). Veno-venous extracorporeal membrane oxygenation (VV-ECMO) is a potential treatment for such cases but may not suffice. We aimed to evaluate the effects of pharmacological interventions for cardiac output (CO) control using ivabradine or beta-blockers for refractory hypoxemia during VV-ECMO.
Methods
The study involved retrospective analysis of consecutive patients with severe ARDS who underwent VV-ECMO at a tertiary university hospital between March 2020 and May 2022. Patients with refractory hypoxemia under VV-ECMO were included. Pharmacological interventions included ivabradine and/or short half-life beta-blockers. The primary endpoint was the change in ECMO flow/CO ratio and secondary endpoints were changes in macrocirculation (mean arterial pressure), oxygenation [arterial saturation (SaO 2 ) and oxygen transport (DO 2 )] and tissue hypoxia (lactate levels).
Results
Out of 70 patients on VV-ECMO, ten had refractory hypoxemia under VV-ECMO and received pharmacological interventions to control CO. The ECMO flow/CO ratio significantly increased with pharmacological intervention overall (from 60% [50–66] to 69% [61–81], p = 0.02), as well as with beta-blockers or ivabradine individually. However, DO 2 decreased, especially with beta-blockers and to some extent with ivabradine. There were no reported immediate adverse events, and lactate levels remained below the anaerobic threshold.
Conclusion
Ivabradine and beta-blockers were clinically well-tolerated and improved the ECMO flow/CO ratio in patients with refractory hypoxemia during VV-ECMO. However, the improvement of arterial oxygenation was associated with decreased DO 2 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- AP-HP, Hôpitaux Universitaires Henri-Mondor, Service de Médecine Intensive Réanimation, 94010, Créteil, France. paul.masi@aphp.fr.
- Univ Paris Est Créteil, CARMAS, 94010, Créteil, France. paul.masi@aphp.fr.
- Service de Réanimation Médicale, Hôpital Henri Mondor, Créteil, France. paul.masi@aphp.fr.
- AP-HP, Hôpitaux Universitaires Henri-Mondor, Service de Médecine Intensive Réanimation, 94010, Créteil, France.
- Univ Paris Est Créteil, CARMAS, 94010, Créteil, France.
- Service de Réanimation Médicale, Hôpital Henri Mondor, Créteil, France.
ORCID-Profile: Paul Masi
Zitieren
APA
Masi, P., Tchatat Wangueu, L., Bagate, F., Plesa, A., Folliguet, T., & Mekontso Dessap, A. (2025). Control of Cardiac Output with Ivabradine or Beta-Blockers for Refractory Hypoxemia under Veno-Venous ECMO for Severe ARDS. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-024-07650-5
Vancouver
Masi P, Tchatat Wangueu L, Bagate F, Plesa A, Folliguet T, Mekontso Dessap A. Control of Cardiac Output with Ivabradine or Beta-Blockers for Refractory Hypoxemia under Veno-Venous ECMO for Severe ARDS. Cardiovascular Drugs and Therapy. 2025. doi:10.1007/s10557-024-07650-5
BibTeX
@article{Masi2025,
author = {Masi, Paul and Tchatat Wangueu, Lionel and Bagate, François and Plesa, Alexandra and Folliguet, Thierry and Mekontso Dessap, Armand},
title = {Control of Cardiac Output with Ivabradine or Beta-Blockers for Refractory Hypoxemia under Veno-Venous ECMO for Severe ARDS},
journal = {Cardiovascular Drugs and Therapy},
year = {2025},
doi = {10.1007/s10557-024-07650-5}
}
EUVIMED